Description: Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf). Target: VEGFR, c-Kit, PDGFR, Autophagy, FLT, Apoptosis, Raf, Ferroptosis. Smiles: Cc1ccc(cc1)S(O)(=O)=O.CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1. References: Wei JC, et...

Sorafenib (Bay 43-9006) is a novel bi-aryl urea compound that inhibits cell proliferation by targeting the ERK pathway and angiogenesis by targeting the receptor tyrosine kinases VEGFR-2 and PDGFR-b and their associated signaling cascades. Although sorafenib was initially developed as a Raf kinase inhibitor...

Sorafenib is a multi-kinase inhibitor that inhibits Raf-1 and B-RAF (IC50s = 6 and 22 µM, respectively), as well as the receptor tyrosine kinases VEGFR2, VEGFR3, PDGFRbeta, FLT3, and c-Kit (IC50s = 90, 15, 20, 57, and 58 nM, respectively). It is selective for these kinases over 12 other kinases, including ERK1,...